GO
Loading...

Enter multiple symbols separated by commas

Novartis AG

More

  • April 23- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing but stuck to its full-year earnings forecast while revenue fell but matched expectations. Lilly earned $530 million, or 50 cents per share, in the quarter, compared with $728 million, or 68 cents per share, a year earlier..

  • Early movers: PBR, MMM, CAT & more Thursday, 23 Apr 2015 | 8:12 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • The Indianapolis- based drugmaker posted a net profit of $529.5 million, or 50 cents per share, for the first quarter ended March 31, compared with a profit of $727.9 million, or 68 cents per share, a year earlier. In January, the company forecast full-year adjusted earnings of $3.10- $3.20 per share, and sales of $19.50- $20 billion. Lilly on Thursday cut its full-year...

  • Swiss exports defy franc surge on U.S., Asia strength Thursday, 23 Apr 2015 | 4:37 AM ET

    ZURICH, April 23- Swiss exports pushed higher in March despite the franc currency's sharp rise against the euro, as surging shipments to the United States, Middle East and Asia more than compensated for a drop-off in sales to the single currency bloc. Sales to the euro zone were down 3.7 percent on a nominal basis, while exports to the United States and Middle East...

  • Novartis warns of currency drag on 2015 earnings Thursday, 23 Apr 2015 | 2:07 AM ET

    Swiss drugmaker Novartis posted declining sales in the first quarter and cautioned that dollar strength may be a bigger-than-expected drag.

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...

  • April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...

  • UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln Tuesday, 14 Apr 2015 | 6:23 PM ET

    Aduro, which counts Johnson& Johnson and Swiss drugmaker Novartis AG among its investors, is selling all the 7 million shares in the offering. To gain access to Aduro's cancer immunotherapy technology, Novartis last month entered into a tie-up worth about $750 million with the company. Novartis Institutes for BioMedical Research Inc, an affiliate of Novartis,...

  • April 14- Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion. Aduro, which counts Johnson& Johnson and Novartis AG among its investors, is selling all the 7 million shares in the offering. The company had previously planned to sell 5 million shares...

  • *Novartis commits $225 mln upfront to private biotech firm. *Novartis also picks top scientist to lead immuno-oncology. March 30- Swiss drugmaker Novartis is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech worth up to $750 million.

  • Payout time in Europe as dividends soar Monday, 30 Mar 2015 | 6:42 AM ET

    Shareholder payouts by large companies in Europe soared over the last financial year, according to new research from Markit.

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • NEW YORK, March 22- As the dollar surged in the last 12 months, David Marcus, head of the Evermore Global Value fund, steadily increased his stake in Europe. Demand for a way to hedge currency exposure while investing in Europe helped the WisdomTree Europe Hedged Equity Fund bring in $5.3 billion in new assets over the first two months of the year, the most of any equity...

  • NEW YORK, March 19- A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The judge denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat drug.

  • LONDON, March 12- Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. For many years the vaccines industry has been dominated by five big companies, but that has shrunk to four with GlaxoSmithKline's purchase of Novartis' business.